2007•BloodRequires access

BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?

Kieron M. Dunleavy, Richard Eric Davis, Ola Landgren, Louis M. Staudt, Wyndham Hopkins Wilson

Abstract

We read with interest the paper by Winter et al[1][1] in which they report the impact of BCL-6 protein expression on outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with rituximab (R-CHOP) or without. These

About this research paper

What this paper is about

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Rituximab, Vincristine, CHOP, Prednisone, Diffuse large B-cell lymphoma, Lymphoma, Cyclophosphamide, Medicine